Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
ATOS's Cash-to-Debt is ranked higher than
85% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ATOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ATOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
88% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. ATOS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATOS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 4
Altman Z-Score: -10.89
Beneish M-Score: -4.98
WACC vs ROIC
15.50%
-922.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -180.49
ATOS's ROE % is ranked lower than
92% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. ATOS: -180.49 )
Ranked among companies with meaningful ROE % only.
ATOS' s ROE % Range Over the Past 10 Years
Min: -972.32  Med: -150.83 Max: -136.71
Current: -180.49
-972.32
-136.71
ROA % -132.38
ATOS's ROA % is ranked lower than
90% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. ATOS: -132.38 )
Ranked among companies with meaningful ROA % only.
ATOS' s ROA % Range Over the Past 10 Years
Min: -7246.67  Med: -149.18 Max: -102.65
Current: -132.38
-7246.67
-102.65
ROC (Joel Greenblatt) % -4032.93
ATOS's ROC (Joel Greenblatt) % is ranked lower than
95% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. ATOS: -4032.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8258.25  Med: -6677.4 Max: -1141.33
Current: -4032.93
-8258.25
-1141.33
3-Year Revenue Growth Rate -88.00
ATOS's 3-Year Revenue Growth Rate is ranked lower than
98% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. ATOS: -88.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88 Max: 102.7
Current: -88
0
102.7
3-Year EBITDA Growth Rate 3.50
ATOS's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. ATOS: 3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 9.2 Max: 54.8
Current: 3.5
3.5
54.8
3-Year EPS without NRI Growth Rate 3.20
ATOS's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ATOS: 3.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ATOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 3.2  Med: 10.3 Max: 57.3
Current: 3.2
3.2
57.3
GuruFocus has detected 1 Warning Sign with Atossa Genetics Inc $ATOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATOS Guru Trades in Q1 2016

Jim Simons 272,562 sh (+148.32%)
» More
Q2 2016

ATOS Guru Trades in Q2 2016

Jim Simons 352,262 sh (+29.24%)
» More
Q3 2016

ATOS Guru Trades in Q3 2016

Jim Simons 41,311 sh (+75.91%)
» More
Q4 2016

ATOS Guru Trades in Q4 2016

Jim Simons 90,811 sh (+119.82%)
» More
» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:MTST, OTCPK:IMEXF, OTCPK:ETAH, OTCPK:ABMC, OTCPK:LEDIF, OTCPK:MEDD, OTCPK:OXIS, NAS:ROSG, NAS:BASI, OTCPK:MNLIF, OTCPK:TBIO, NAS:CBMX, OTCPK:BZYR, NAS:IDXG, NAS:BIOP, OTCPK:MDIT, OTCPK:MYAN, OTCPK:CRRVF, NAS:GENE, OTCPK:GNWSF » details
Traded in other countries:YAG1.Germany,
Atossa Genetics Inc is a healthcare company. The Company is focused on improving breast health through the development of a suite of laboratory services, medical devices and therapeutics.

Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.

Ratios

vs
industry
vs
history
PB Ratio 1.01
ATOS's PB Ratio is ranked higher than
92% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ATOS: 1.01 )
Ranked among companies with meaningful PB Ratio only.
ATOS' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.48 Max: 22.34
Current: 1.01
0.3
22.34
Current Ratio 5.28
ATOS's Current Ratio is ranked higher than
79% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ATOS: 5.28 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.72 Max: 16.36
Current: 5.28
0.01
16.36
Quick Ratio 5.28
ATOS's Quick Ratio is ranked higher than
81% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ATOS: 5.28 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.7 Max: 16.36
Current: 5.28
0.01
16.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.30
ATOS's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. ATOS: -36.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.8  Med: -39.2 Max: -36.3
Current: -36.3
-45.8
-36.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.60
ATOS's Price-to-Net-Cash is ranked higher than
94% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.06 vs. ATOS: 1.60 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.56  Med: 7.36 Max: 650
Current: 1.6
1.56
650
Price-to-Net-Current-Asset-Value 1.52
ATOS's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. ATOS: 1.52 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.48  Med: 5.84 Max: 150
Current: 1.52
1.48
150
Price-to-Tangible-Book 1.41
ATOS's Price-to-Tangible-Book is ranked higher than
90% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. ATOS: 1.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.37  Med: 5.28 Max: 93.9
Current: 1.41
1.37
93.9
Earnings Yield (Greenblatt) % -651.96
ATOS's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ATOS: -651.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -731.25  Med: 340.4 Max: 113837.8
Current: -651.96
-731.25
113837.8

More Statistics

EPS (TTM) $ -3.70
Beta1.74
Short Percentage of Float10.31%
52-Week Range $1.30 - 7.35
Shares Outstanding (Mil)3.79

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -2.57 -3.57 -2.04
EPS without NRI ($) -2.57 -3.57 -2.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics (ATOS) Soars on Distribution Deal, Conn's (CONN) Rating Boosted Feb 09 2015 

More From Other Websites
Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its... Jan 09 2017
Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017 Jan 05 2017
Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor Dec 23 2016
Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor Dec 23 2016
ATOSSA GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 12 2016
Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016 Dec 01 2016
ATOSSA GENETICS INC Financials Nov 22 2016
ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 14 2016
ATOSSA GENETICS INC Files SEC form 10-Q, Quarterly Report Nov 14 2016
Atossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update Nov 14 2016
Atossa Genetics Announces Third Quarter 2016 Financial Results and Provides Company Update Nov 14 2016
Atossa Genetics to Provide Company Update and Discuss Third Quarter 2016 Financial Results on... Nov 10 2016
Atossa Genetics to Provide Company Update and Discuss Third Quarter 2016 Financial Results on... Nov 10 2016
Atossa Genetics Inc. to Present at Upcoming Investor Conferences in October 2016 Oct 14 2016
Atossa Genetics Inc. to Present at Upcoming Investor Conferences in October 2016 Oct 14 2016
SeeThruEquity Issues Update on Atossa Genetics, Inc. Oct 03 2016
Atossa Genetics, Inc. Regains Compliance With NASDAQ Listing Requirement Sep 13 2016
Atossa Genetics, Inc. Regains Compliance With NASDAQ Listing Requirement Sep 13 2016
Atossa Genetics, Inc. to Present at Upcoming Investor Conferences in September 2016 Sep 12 2016
Atossa Genetics, Inc. to Present at Upcoming Investor Conferences in September 2016 Sep 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)